271 related articles for article (PubMed ID: 29308539)
1. Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
van Steen SC; Woodward M; Chalmers J; Li Q; Marre M; Cooper ME; Hamet P; Mancia G; Colagiuri S; Williams B; Grobbee DE; DeVries JH;
Diabetologia; 2018 Apr; 61(4):780-789. PubMed ID: 29308539
[TBL] [Abstract][Full Text] [Related]
2. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
[TBL] [Abstract][Full Text] [Related]
3. New insights from ADVANCE.
Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
[TBL] [Abstract][Full Text] [Related]
4. ADVANCE: breaking new ground in type 2 diabetes.
Chalmers J; Perkovic V; Joshi R; Patel A
J Hypertens Suppl; 2006 Aug; 24(5):S22-8. PubMed ID: 16936533
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
Chalmers J; Arima H; Woodward M; Mancia G; Poulter N; Hirakawa Y; Zoungas S; Patel A; Williams B; Harrap S
Hypertension; 2014 Feb; 63(2):259-64. PubMed ID: 24324048
[TBL] [Abstract][Full Text] [Related]
6. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
van der Leeuw J; Visseren FL; Woodward M; Zoungas S; Kengne AP; van der Graaf Y; Glasziou P; Hamet P; MacMahon S; Poulter N; Grobbee DE; Chalmers J
Hypertension; 2015 Jan; 65(1):115-21. PubMed ID: 25312436
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
8. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Batty GD; Li Q; Czernichow S; Neal B; Zoungas S; Huxley R; Patel A; de Galan BE; Woodward M; Hamet P; Harrap SB; Poulter N; Chalmers J;
J Am Coll Cardiol; 2010 Nov; 56(23):1908-13. PubMed ID: 21109113
[TBL] [Abstract][Full Text] [Related]
9. Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Selvin E; Wang D; McEvoy JW; Juraschek SP; Lazo M; Hamet P; Cooper ME; Marre M; Williams B; Harrap S; Chalmers J; Woodward M
Diabetes Obes Metab; 2019 Aug; 21(8):2017-2023. PubMed ID: 31050156
[TBL] [Abstract][Full Text] [Related]
10. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
13. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
14. Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
Rahman F; McEvoy JW; Ohkuma T; Marre M; Hamet P; Harrap S; Mancia G; Rodgers A; Selvin E; Williams B; Muntner P; Chalmers J; Woodward M
Hypertension; 2019 Jun; 73(6):1291-1299. PubMed ID: 31030606
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
16. [ADVANCE study: objectives, design and current status].
Chalmers J
Drugs; 2003; 63 Spec No 1():39-44. PubMed ID: 12708881
[TBL] [Abstract][Full Text] [Related]
17. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Waeber B
J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
[TBL] [Abstract][Full Text] [Related]
18. ADVANCE: action in diabetes and vascular disease.
Patel A; Chalmers J; Poulter N
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
[TBL] [Abstract][Full Text] [Related]
19. [The prevention of the hypertension related damage in type-2 diabetes: the first step of the ADVANCE trial].
Nagy V
Orv Hetil; 2008 Jan; 149(1):19-22. PubMed ID: 18089478
[TBL] [Abstract][Full Text] [Related]
20. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
